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Previewsthe extensions showed the opposite
resemblance. The authors concluded
that recognition of the ground state by
M48U1 and M48U7 is more favorable
energetically, contributing to their higher
affinities. More expansive neutralization
studies (180 isolate panel) revealed potent
activity against all except those from
Clade A/E. The presence of His at position
375 of gp120 of these isolates (instead of
the canonical Ser) is interpreted to explain
this resistance, because the His partially
fills the Phe43 pocket, thereby hindering
access of the extensions (but not CD4 or
the mimetics lacking the extensions).
This is consistent with previous findings
that resistance to M48U1 involves the
substitution of Ser375 with more bulky
residues. The results are discussed in
terms of a new mechanism of action of
CD4 binding site ligands beyond the pre-
viously described avidity (multivalent
forms) and avoidance of conformational
change (e.g., mAb VRC01), namely opti-
mization of the fitting of the hydrophobic
extensions within the interfacial Phe43
cavity.
These new agents and the structural
elucidation of the mechanisms underlying
their enhanced anti-HIV potencies prom-
ise to guide further design of novel
neutralizing agents based on optimal872 Structure 21, June 4, 2013 ª2013 Elseviefitting of extensions into the Phe43 cavity.
The recent ex vivo and nonhuman primate
studies with M48U1 as a vaginal microbi-
cide to prevent HIV-1 sexual transmission
(Dereuddre-Bosquet et al., 2012) are
highly promising for the potential antiviral
use of these miniproteins. Structure-
guided design and analysis thus continue
to pave the way for the development of
new CD4 mimetics that not only cap the
Phe43 cavity, but also fit energetically
favorable extensions deep within its
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E3 ubiquitin ligases are the last of an enzyme trio that covalently modifies proteins with ubiquitin, facilitating
various cellular functions. In this issue of Structure, Duda and colleagues provide the structural basis for the
autoinhibited Ariadne-family of E3-ubiquitin ligases.Ubiquitination, a covalent attachment of
the 76-amino-acid polypeptide ubiquitin
(Ub) to lysine residues of target proteins,
is an important post-translational modi-
fication that controls a wide range of
cellular processes. Three enzymatic sys-
tems facilitate covalent modification ofproteins by Ub: E1 activating enzymes,
E2 conjugating enzymes, and E3 Ub
ligases. First, Ub is activated via adeny-
lation by E1 and is linked subsequently
to a cysteine residue on the enzyme as a
thioester complex. Ub is then transferred
to the catalytic cysteine on an E2 viatransthiolation. The final step of the ubiq-
uitination cascade involves the transfer
of Ub from the thioester-linked E2 enzyme
(E2Ub) to a Lys residue of the substrate
mediated by an E3 ligase. Two distinct
mechanisms exist for ligation of Ub to
substrates. A homologous to the E6AP
Figure 1. A Cartoon Representation of the Autoinhibited and Active
State of the RBR E3 Ligase, HHARI
The C-terminal Ariadne domain of HHARI folds back onto RING2, capping the
catalytic cysteine (Cys357), resulting in autoinhibition of ligase activity even
when RING1 is bound to UbE2. Ligase activity is presumed to commence
upon displacement of Ariadne, likely resulting from either posttranslational
modification (PTM) or binding of an unknown Ariadne binding protein (ABP),
leaving the catalytic cysteine exposed for Ub transfer.
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Previewscarboxy terminus (HECT)-
type E3 ligase, so named
because of the presence of a
C-terminally located HECT
domain, transfers Ub from
the active-site cysteine of an
E2Ub complex to the cata-
lytic cysteine within the
HECT domain, forming an
E3Ub thioester intermediate
prior to depositing Ub onto a
Lys residue of the substrate.
The overwhelming majority
of E3 ligases in the human
genome, however, are RING
E3 ligases, which employ a
different mechanism. RING
E3s contain a RING domain
that coordinates a pair of
Zn2+ ions, which is used to re-
cruit E2Ub (Deshaies and
Joazeiro, 2009). Contrary to
HECT E3s, RING E3s do not
have a catalytic residue.
Instead, acting solely as a
scaffold, they bring the
E2Ub complex and sub-
strate together, thereby allowing the
direct transfer of Ub from the catalytic
cysteine of E2s to Lys residues of the
substrate.
In the past, eukaryotic E3s have been
classified as HECT or RING ligases, with
distinct mechanistic features, according
to their structure. But recently, in a sig-
nificant work, Wenzel et al. (2011) pro-
vided first evidence in support of a
RING-HECT hybrid mechanism used by
the novel RING1-in-between-ring (IBR)-
RING2 (RBR) ligase human homolog of
Ariadne (HHARI), the founding member
of a group of conserved eukaryotic
ligases. The well-known members of this
group now include the Parkinson’s dis-
ease (PD)-associated protein Parkin,
which is linked to autosomal recessive ju-
venile PD, and linear Ub chain assembly
complex (LUBAC), which functions in
NF-kB signaling. RBR E3s can be charac-
terized by a canonical RING1 domain,
typical of those found in RING E3s, and
the presence of additional IBR domain fol-
lowed by the RING2 domain, which de-
fines them as a unique group of ligases.
Like the RING domain of RING E3s, the
RING1 domain is known to recruit
E2Ub, with the proposed HECT type of
mechanism arising due to the presence
of an invariant cysteine in the RING2domain, which is thought to form a thio-
ester intermediate with Ub taken from
the active-site cysteine of the E2 before
ultimately transferring it to a Lys residue
on the substrate. Although biochemical
evidence supported the RING-HECT
hybrid mechanism (Wenzel et al., 2011),
structural understanding of this unique
class of ligases remained elusive. Struc-
tures of RING1, IBR, and RING2 domains
from different RBRs have been character-
ized before, but not together in a full-
length construct. Previous biochemical
studies with RBRs showed that the full-
length proteins are incapable of catalytic
activity, but constructs encompassing
the RBR core are capable of autoubiquiti-
nation, a biochemical read-out of their
enzymatic activity. This suggests that
full-length RBRs are autoinhibited, but
the structural basis of this was not known.
In this issue of Structure, Duda et al.
(2013) provide the first X-ray crystal struc-
ture of full-length HHARI, an Ariadne
family of RBR E3 Ub ligases. Like Parkin
and HOIP (one of the RBRs of the hetero-
dimeric LUBAC E3), the full-length HHARI
remains in an inactive state, but unlike
Parkin, HHARI is still capable of binding
to E2, suggesting that the protein is in a
conformation that prevents its E3 ligase
activity. HHARI is an extended 90 A˚-longStructure 21, June 4, 2013 ª2013 Elseassembly of multiple do-
mains: a UBA-like domain
comprised of a three-helix
bundle, RING1, a two-helix
RING1-to-IBR linker, the
IBR, RING2, and the Ariadne
domain. The IBR and RING1




has a novel Zn2+-binding fold
containing eight cysteines,
seven of which are involved
in Zn2+ coordination, with the
lone unliganded cysteine,
Cys357, required for autoubi-
quitination of HHARI.
The structural basis for
HHARI autoinhibition arises
from the C-terminal Ariadne
domain effectively capping
RING2, thus masking the cat-
alytic cysteine, rendering it
unable to be ubiquitinated.
The Ariadne domain buries
1,000 A˚2 of total surface ontop of RING2, forming 122 contacts.
When the Ariadne domain was deleted
from HHARI, a reversal of the autoinhi-
bited state was seen, and a complemen-
tary experiment showed that an isolated
Ariadne domain also inhibits Ub transfer
when added in trans to a construct of
HHARI lacking the Ariadne domain, sug-
gesting that the release of the Ariadne
domain promotes E2-E3 Ub transfer.
The X-ray structure of HHARI reported
here by Duda et al. (2013) provides un-
ambiguous evidence showing that the
inherent lack of HHARI’s E3 ligase activity
is hardwired in its structure. A similar
mechanism of autoinhibition is perhaps
used by other members of the Ariadne
family of RBRs aswell, although it remains
to be demonstrated. Almost coinciding
with this report, the X-ray structure of
full-length Parkin is also being reported
(Trempe et al., 2013). The structure of
Parkin reveals one more example of an
autoinhibited RBR E3. In Parkin, both the
E2 binding site on RING1 and the catalytic
site on RING2 are blocked by close pack-
ing against other domains unique to this
protein (Trempe et al., 2013). Together,
these structural studies strongly indicate
that autoinhibition may be a common
property of RBR E3s, perhaps to avoid
autoubiquitination that may render thesevier Ltd All rights reserved 873
Structure
Previewsenzymes susceptible to rapid, untimely
degradation by proteasome, as specu-
lated by Duda et al. (2013).
This full-length HHARI structure, like
Parkin, drives the field into pondering the
mechanism for activation. Parkin un-
dergoes PINK1-dependent phosphoryla-
tion to turn into an active form; however,
the mechanism is not fully understood
(Trempe et al., 2013). Similarly, the
Ariadne domain needs to be removed
from RING2 to undergo thioester bond
formation and subsequent Ub ligase ac-
tivity, which, as the authors suggest,
could be facilitated either by a post-
translational modification or an Ariadne874 Structure 21, June 4, 2013 ª2013 Elseviebinding partner (Figure 1). Future studies
will show us the mechanism of catalytic
activation of these intriguing ligases. The
structures of HHARI and Parkin lay the
foundation of an exciting array of further
structural work that will reveal mecha-
nistic details of RING-HECT hybrid catal-
ysis of Ub transfer.ACKNOWLEDGMENTS
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